Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Progress in Neurobiology

Volumn 144, Issue , 2016, Pages 142-157

  Echeverria, Valentina ^a,b,c   Yarkov, Alex ^a   Aliev, Gjumrakch ^d,e  

^a UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d GALLY International Biomedical Research Consulting LLC   (United States)

^e University of Atlanta   (United States)

Author keywords

Alzheimer's disease; Autoimmunity; Glia; Neuroinflammation; Nicotinic receptors; Prostaglandins

Indexed keywords

ALKALOID; AMYLOID BETA PROTEIN ANTIBODY; ANATABINE; BUNGAROTOXIN RECEPTOR; COTININE; CRENEZUMAB; GALANTAMINE; GANTENERUMAB; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT GAMMA INTERFERON; TAU PROTEIN; UNCLASSIFIED DRUG; NICOTINIC AGENT;

ALLOSTERISM; ALZHEIMER DISEASE; ASTROCYTE; CELL ACTIVATION; COGNITIVE DEFECT; HUMAN; META ANALYSIS (TOPIC); MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; METABOLISM; PHYSIOLOGY;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ALZHEIMER DISEASE; ANIMALS; HUMANS; INFLAMMATION; NEUROIMMUNOMODULATION; NICOTINIC AGONISTS;

EID: 84955313377     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2016.01.002     Document Type: Review

References (246)

1. Abdul, H.M., Sama, M.A., Furman, J.L., Mathis, D.M., Beckett, T.L., Weidner, A.M., Patel, E.S., Baig, I., Murphy, M.P., LeVine, H. 3rd, Kraner, S.D., Norris, C.M., Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J. Neurosci. 29 (2009), 12957–12969.
2. Ahmad, A.S., Zhuang, H., Echeverria, V., Dore, S., Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J. Neurotrauma 23 (2006), 1895–1903.
3. Ahmad, M., Saleem, S., Zhuang, H., Ahmad, A.S., Echeverria, V., Sapirstein, A., Dore, S., 1-hydroxyPGE reduces infarction volume in mouse transient cerebral ischemia. Eur. J. Neurosci. 23 (2006), 35–42.
4. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., Wyss-Coray, T., Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000), 383–421.
5. Aliev, G., Obrenovich, M.E., Smith, M.A., Perry, G., Hypoperfusion, mitochondria failure, oxidative stress, and alzheimer disease. J. Biomed. Biotechnol. 2003 (2003), 162–163.
6. Alkadhi, K.A., Alzoubi, K.H., Srivareerat, M., Tran, T.T., Chronic psychosocial stress exacerbates impairment of synaptic plasticity in beta-amyloid rat model of Alzheimer's disease: prevention by nicotine. Curr. Alzheimer Res. 8 (2011), 718–731.
7. Alkadhi, K.A., Srivareerat, M., Tran, T.T., Intensification of long-term memory deficit by chronic stress and prevention by nicotine in a rat model of Alzheimer's disease. Mol. Cell Neurosci. 45 (2010), 289–296.
8. Amin, J., Paquet, C., Baker, A., Asuni, A.A., Love, S., Holmes, C., Hugon, J., Nicoll, J.A., Boche, D., Effect of Abeta immunisation on hyperphosphorylated tau: a potential role for GSK-3beta. Neuropathol. Appl. Neurobiol. 41 (2014), 445–457.
9. Appel, S.H., A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10 (1981), 499–505.
10. Arendash, G.W., Lewis, J., Leighty, R.E., McGowan, E., Cracchiolo, J.R., Hutton, M., Garcia, M.F., Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res. 1012 (2004), 29–41.
11. Aronson, S., Van Baelen, B., Kavanagh, S., Schwalen, S., Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging 26 (2009), 231–239.
12. Association, A.s., Alzheimer's Association Report 2015 Alzheimer's disease facts and figures. Alzheimer's Dement. 11 (2015), 332–384.
13. Asuni, A.A., Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27 (2007), 9115–9129.
14. Bagaitkar, J., Zeller, I., Renaud, D.E., Scott, D.A., Cotinine inhibits the pro-inflammatory response initiated by multiple cell surface Toll-like receptors in monocytic THP cells. Tob. Induc. Dis., 10, 2012, 18.
15. Bales, K.R., Du, Y., Dodel, R.C., Yan, G.M., Hamilton-Byrd, E., Paul, S.M., The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain Res. Mol. Brain Res. 57 (1998), 63–72.
16. Bard, F., Cannon, C., Barbour, R., Burke, R.L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., Kholodenko, D., Lee, M., Lieberburg, I., Motter, R., Nguyen, M., Soriano, F., Vasquez, N., Weiss, K., Welch, B., Seubert, P., Schenk, D., Yednock, T., Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6 (2000), 916–919.
17. Barreto, G.E., Iarkov, A., Moran, V.E., Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease. Front. Aging Neurosci., 6, 2015, 340.
18. Bartus, R.T., Dean, R.L. 3rd, Beer, B., Lippa, A.S., The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982), 408–414.
19. Beach, T.G., Walker, R., McGeer, E.G., Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 2 (1989), 420–436.
20. Benarroch, E.E., Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology 81 (2013), 1079–1088.
21. Bhattacharya, S., Haertel, C., Maelicke, A., Montag, D., Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease. PLoS ONE, 9, 2014, e89454.
22. Bhattacharya, S., Maelicke, A., Montag, D., Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5× familial Alzheimer's disease mice. J. Alzheimers Dis. 46 (2015), 123–136.
23. Bi, M., Ittner, A., Ke, Y.D., Gotz, J., Ittner, L.M., Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE, 6, 2011, e26860.
24. Birks, J., Grimley Evans, J., Iakovidou, V., Tsolaki, M., Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev., 2, 2000, CD001191.
25. Birks, J., Grimley Evans, J., Iakovidou, V., Tsolaki, M., Holt, F.E., Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev., 4, 2009, CD001191.
26. Blain, H., Jouzeau, J.Y., Blain, A., Terlain, B., Trechot, P., Touchon, J., Netter, P., Jeandel, C., Non-steroidal anti-inflammatory drugs with selectivity for cyclooxygenase-2 in Alzheimer's disease. Rationale and perspectives. Presse Med. 29 (2000), 267–273.
27. Boche, D., Zotova, E., Weller, R.O., Love, S., Neal, J.W., Pickering, R.M., Wilkinson, D., Holmes, C., Nicoll, J.A., Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 131 (2008), 3299–3310.
28. Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., Rosenmann, H., Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68 (2009), 314–325.
29. Boutajangout, A., Ingadottir, J., Davies, P., Sigurdsson, E.M., Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118 (2011), 658–667.
30. Boutajangout, A., Quartermain, D., Sigurdsson, E.M., Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 30 (2010), 16559–16566.
31. Brown, K.C., Lau, J.K., Dom, A.M., Witte, T.R., Luo, H., Crabtree, C.M., Shah, Y.H., Shiflett, B.S., Marcelo, A.J., Proper, N.A., Hardman, W.E., Egleton, R.D., Chen, Y.C., Mangiarua, E.I., Dasgupta, P., MG624, an alpha7-nAChR antagonist, inhibits angiogenesis via the Egr-1/FGF2 pathway. Angiogenesis 15 (2012), 99–114.
32. Brun, A., Englund, E., Brain changes in dementia of Alzheimer's type relevant to new imaging diagnostic methods. Prog. Neuropsychopharmacol. Biol. Psychiatry 10 (1986), 297–308.
33. Buckwalter, M.S., Wyss-Coray, T., Modelling neuroinflammatory phenotypes in vivo. J. Neuroinflammation., 1, 2004, 10.
34. Buttini, M., Westland, C.E., Masliah, E., Yafeh, A.M., Wyss-Coray, T., Mucke, L., Novel role of human CD4 molecule identified in neurodegeneration. Nat. Med. 4 (1998), 441–446.
35. Carmeli, C., Donati, A., Antille, V., Viceic, D., Ghika, J., von Gunten, A., Clarke, S., Meuli, R., Frackowiak, R.S., Knyazeva, M.G., Demyelination in mild cognitive impairment suggests progression path to Alzheimer's disease. PLoS ONE, 8, 2013, e72759.
36. Carrasco, E., Werner, P., Casper, D., Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress. Neurosci. Lett. 441 (2008), 44–49.
37. Carson, R., Craig, D., Hart, D., Todd, S., McGuinness, B., Johnston, J.A., O'Neill, F.A., Ritchie, C.W., Passmore, A.P., Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease. Neuromolecular. Med. 10 (2008), 377–384.
38. Chang, S.L., Connaghan, K.P., Wei, Y., Li, M.D., NeuroHIV and use of addictive substances. Int. Rev. Neurobiol. 118 (2010), 403–440.
39. Changeux, J.P., Bertrand, D., Corringer, P.J., Dehaene, S., Edelstein, S., Lena, C., Le Novere, N., Marubio, L., Picciotto, M., Zoli, M., Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res. Brain Res. Rev. 26 (1998), 198–216.
40. Changeux, J.P., Edelstein, S.J., Allosteric receptors after 30 years. Neuron 21 (1998), 959–980.
41. Changeux, J.P., Edelstein, S.J., Allosteric mechanisms of signal transduction. Science 308 (2005), 1424–1428.
42. Chen, L., Yamada, K., Nabeshima, T., Sokabe, M., alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50 (2006), 254–268.
43. Cohen, R.M., Rezai-Zadeh, K., Weitz, T.M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y., Vasilevko, V., Glabe, C.G., Breunig, J.J., Rakic, P., Davtyan, H., Agadjanyan, M.G., Kepe, V., Barrio, J.R., Bannykh, S., Szekely, C.A., Pechnick, R.N., Town, T., A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J. Neurosci. 33 (2013), 6245–6256.
44. Condello, C., Yuan, P., Schain, A., Grutzendler, J., Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat. Commun., 6, 2015, 6176.
45. Courtney, C., Farrell, D., Gray, R., Hills, R., Lynch, L., Sellwood, E., Edwards, S., Hardyman, W., Raftery, J., Crome, P., Lendon, C., Shaw, H., Bentham, P., Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363 (2004), 2105–2115.
46. Craig, L.A., Hong, N.S., McDonald, R.J., Revisiting the cholinergic hypothesis in the development of Alzheimer's disease. Neurosci. Biobehav. Rev. 35 (2011), 1397–1409.
47. Cudaback, E., Jorstad, N.L., Yang, Y., Montine, T.J., Keene, C.D., Therapeutic implications of the prostaglandin pathway in Alzheimer's disease. Biochem. Pharmacol. 88 (2014), 565–572.
48. D'Andrea, M.R., Add Alzheimer's disease to the list of autoimmune diseases. Med. Hypotheses 64 (2005), 458–463.
49. Davalos, D., Grutzendler, J., Yang, G., Kim, J.V., Zuo, Y., Jung, S., Littman, D.R., Dustin, M.L., Gan, W.B., ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8 (2005), 752–758.
50. de la Torre, J.C., Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med. 370 (2014), 1459–1460.
51. De Simone, R., Ajmone-Cat, M.A., Carnevale, D., Minghetti, L., Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation, 2, 2005, 4.
52. DeMattos, R.B., Bales, K.R., Cummins, D.J., Dodart, J.C., Paul, S.M., Holtzman, D.M., Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 98 (2001), 8850–8855.
53. Desai, M.K., Mastrangelo, M.A., Ryan, D.A., Sudol, K.L., Narrow, W.C., Bowers, W.J., Early oligodendrocyte/myelin pathology in Alzheimer's disease mice constitutes a novel therapeutic target. Am. J. Pathol. 177 (2010), 1422–1435.
54. Dhib-Jalbut, S., Arnold, D.L., Cleveland, D.W., Fisher, M., Friedlander, R.M., Mouradian, M.M., Przedborski, S., Trapp, B.D., Wyss-Coray, T., Yong, V.W., Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J. Neuroimmunol. 176 (2006), 198–215.
55. Dickson, D.W., Lee, S.C., Mattiace, L.A., Yen, S.H., Brosnan, C., Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia 7 (1993), 75–83.
56. Dineley, K.T., Pandya, A.A., Yakel, J.L., Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol. Sci. 36 (2015), 96–108.
57. Doody, R.S., Farlow, M., Aisen, P.S., Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med., 370, 2014, 1460.
58. Dore, S., GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor. Trends Pharmacol. Sci. 27 (2006), 458–460.
59. Dunlop, J., Lock, T., Jow, B., Sitzia, F., Grauer, S., Jow, F., Kramer, A., Bowlby, M.R., Randall, A., Kowal, D., Gilbert, A., Comery, T.A., Larocque, J., Soloveva, V., Brown, J., Roncarati, R., Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine(2B/C) receptor antagonist SB-206553 (3,5-dihydro-5-methyl-N-3-pyridinylbenzo[1,2-b:4,5-b′]di pyrrole-1(2H)-carboxamide). J. Pharmacol. Exp. Ther. 328 (2009), 766–776.
60. Dwoskin, L.P., Teng, L., Buxton, S.T., Crooks, P.A., (S)-(−)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther. 288 (1999), 905–911.
61. Echeverria, V., Clerman, A., Dore, S., Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur. J. Neurosci. 22 (2005), 2199–2206.
62. Echeverria, V., Zeitlin, R., Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci. Ther. 18 (2012), 517–523.
63. Echeverria, V., Zeitlin, R., Burgess, S., Patel, S., Barman, A., Thakur, G., Mamcarz, M., Wang, L., Sattelle, D.B., Kirschner, D.A., Mori, T., Leblanc, R.M., Prabhakar, R., Arendash, G.W., Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. J. Alzheimers Dis. 24 (2011), 817–835.
64. Farlow, M., Arnold, S.E., van Dyck, C.H., Aisen, P.S., Snider, B.J., Porsteinsson, A.P., Friedrich, S., Dean, R.A., Gonzales, C., Sethuraman, G., DeMattos, R.B., Mohs, R., Paul, S.M., Siemers, E.R., Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 8 (2012), 261–271.
65. Feldman, H.H., Pirttila, T., Dartigues, J.F., Everitt, B., Van Baelen, B., Brashear, H.R., Berlin, J.A., Battisti, W.P., Kavanagh, S., Analyses of mortality risk in patients with dementia treated with galantamine. Acta Neurol. Scand. 119 (2009), 22–31.
66. Feldman, H.H., Pirttila, T., Dartigues, J.F., Everitt, B., Van Baelen, B., Schwalen, S., Kavanagh, S., Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int. J. Geriatr. Psychiatry 24 (2009), 479–488.
67. Foster, T.C., Sharrow, K.M., Masse, J.R., Norris, C.M., Kumar, A., Calcineurin links Ca2+ dysregulation with brain aging. J. Neurosci. 21 (2001), 4066–4073.
68. Fuller, J.P., Stavenhagen, J.B., Teeling, J.L., New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease. Front. Neurosci., 8, 2014, 235.
69. Fuxe, K., Everitt, B.J., Hokfelt, T., On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol. Biochem. Behav. 10 (1979), 671–677.
70. Galvis, G., Lips, K.S., Kummer, W., Expression of nicotinic acetylcholine receptors on murine alveolar macrophages. J. Mol. Neurosci. 30 (2006), 107–108.
71. Garwood, C.J., Pooler, A.M., Atherton, J., Hanger, D.P., Noble, W., Astrocytes are important mediators of Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis., 2, 2011, e167.
72. Gatson, J.W., Simpkins, J.W., Uteshev, V.V., High therapeutic potential of positive allosteric modulation of alpha7 nAChRs in a rat model of traumatic brain injury: proof-of-concept. Brain Res. Bull. 112 (2015), 35–41.
73. Ghezzi, L., Scarpini, E., Galimberti, D., Disease-modifying drugs in Alzheimer's disease. Drug Des. Devel. Ther. 7 (2013), 1471–1478.
74. Ghosh, S., Wu, M.D., Shaftel, S.S., Kyrkanides, S., LaFerla, F.M., Olschowka, J.A., O'Banion, M.K., Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J. Neurosci. 33 (2013), 5053–5064.
75. Gorkiewicz, T., Szczuraszek, K., Wyrembek, P., Michaluk, P., Kaczmarek, L., Mozrzymas, J.W., Matrix metalloproteinase-9 reversibly affects the time course of NMDA-induced currents in cultured rat hippocampal neurons. Hippocampus 20 (2010), 1105–1108.
76. Gotz, J., Chen, F., Barmettler, R., Nitsch, R.M., Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276 (2001), 529–534.
77. Gotz, J., Gladbach, A., Pennanen, L., van Eersel, J., Schild, A., David, D., Ittner, L.M., Animal models reveal role for tau phosphorylation in human disease. Biochim. Biophys. Acta 1802 (2010), 860–871.
78. Gotz, J., Matamales, M., Gotz, N.N., Ittner, L.M., Eckert, A., Alzheimer's disease models and functional genomics-How many needles are there in the haystack?. Front. Physiol., 3, 2012, 320.
79. Guo, N., Yao, W., Wang, S.R., Zhu, J., Huang, D., Zuo, P.L., Kang, X.J., Fu, C.L., Zhou, Z., Zhang, B., Nicotine dynamically modulates dopamine clearance in rat striatum in vivo. Neurochem. Int. 60 (2012), 355–359.
80. Hedayat, M., Takeda, K., Rezaei, N., Prophylactic and therapeutic implications of toll-like receptor ligands. Med. Res. Rev. 32 (2012), 294–325.
81. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Bullock, R., Love, S., Neal, J.W., Zotova, E., Nicoll, J.A., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372 (2008), 216–223.
82. Hoozemans, J.J., Veerhuis, R., Rozemuller, A.J., Eikelenboom, P., Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr. Drug Targets 4 (2003), 461–468.
83. Horiuchi, M., Maezawa, I., Itoh, A., Wakayama, K., Jin, L.W., Itoh, T., Decarli, C., Amyloid beta1–42 oligomer inhibits myelin sheet formation in vitro. Neurobiol. Aging 33 (2012), 499–509.
84. Hu, C., Adedokun, O., Ito, K., Raje, S., Lu, M., Confirmatory population pharmacokinetic analysis for bapineuzumab phase 3 studies in patients with mild to moderate Alzheimer's disease. J. Clin. Pharmacol. 55 (2015), 221–229.
85. Hurst, R.S., Hajos, M., Raggenbass, M., Wall, T.M., Higdon, N.R., Lawson, J.A., Rutherford-Root, K.L., Berkenpas, M.B., Hoffmann, W.E., Piotrowski, D.W., Groppi, V.E., Allaman, G., Ogier, R., Bertrand, S., Bertrand, D., Arneric, S.P., A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J. Neurosci. 25 (2005), 4396–4405.
86. Inestrosa, N.C., Godoy, J.A., Vargas, J.Y., Arrazola, M.S., Rios, J.A., Carvajal, F.J., Serrano, F.G., Farias, G.G., Nicotine prevents synaptic impairment induced by amyloid-beta oligomers through alpha7-nicotinic acetylcholine receptor activation. Neuromol. Med. 15 (2013), 549–569.
87. Inglese, M., Benedetti, B., Filippi, M., The relation between MRI measures of inflammation and neurodegeneration in multiple sclerosis. J. Neurol. Sci. 233 (2005), 15–19.
88. Ishizawa, T., Sahara, N., Ishiguro, K., Kersh, J., McGowan, E., Lewis, J., Hutton, M., Dickson, D.W., Yen, S.H., Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am. J. Pathol. 163 (2003), 1057–1067.
89. Itagaki, S., McGeer, P.L., Akiyama, H., Presence of T-cytotoxic suppressor and leucocyte common antigen positive cells in Alzheimer's disease brain tissue. Neurosci. Lett. 91 (1988), 259–264.
90. Jones, C.K., Byun, N., Bubser, M., Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology 37 (2012), 16–42.
91. Kamat, P.K., Swarnkar, S., Rai, S., Kumar, V., Tyagi, N., Astrocyte mediated MMP-9 activation in the synapse dysfunction: an implication in Alzheimer disease. Ther. Targets Neurol. Dis., 1, 2014, e243.
92. Kavanagh, S., Gaudig, M., Van Baelen, B., Adami, M., Delgado, A., Guzman, C., Jedenius, E., Schauble, B., Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta Neurol. Scand. 124 (2011), 302–308.
93. Kavanagh, S., Howe, I., Brashear, H.R., Wang, D., van Baelen, B., Todd, M., Schwalen, S., Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. Curr. Alzheimer Res. 8 (2011), 175–186.
94. Kavanagh, S., Van Baelen, B., Schauble, B., Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. J. Alzheimers Dis. 27 (2011), 521–530.
95. Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A., Shimohama, S., Galantamine modulates nicotinic receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun. 325 (2004), 976–982.
96. Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., Akaike, A., Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity. Brain Res. 792 (1998), 331–334.
97. Kitazawa, M., Cheng, D., Tsukamoto, M.R., Koike, M.A., Wes, P.D., Vasilevko, V., Cribbs, D.H., LaFerla, F.M., Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal beta-catenin pathway function in an Alzheimer's disease model. J. Immunol. 187 (2011), 6539–6549.
98. Kosenko, E.A., Solomadin, I.N., Tikhonova, L.A., Reddy, V.P., Aliev, G., Kaminsky, Y.G., Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid-beta peptides, systemic ammonia and erythrocyte energy metabolism. CNS Neurol. Disord. Drug Targets 13 (2014), 112–119.
99. Lalancette-Hebert, M., Gowing, G., Simard, A., Weng, Y.C., Kriz, J., Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27 (2007), 2596–2605.
100. Lambracht-Washington, D., Rosenberg, R.N., Anti-amyloid beta to tau—based immunization: developments in immunotherapy for Alzheimer disease. Immunotargets Ther. 2013 (2013), 105–114.
101. Laske, C., Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med., 370, 2014, 1459.
102. Lassmann, H., Multiple sclerosis: is there neurodegeneration independent from inflammation?. J. Neurol. Sci. 259 (2007), 3–6.
103. LaVoie, E.J., Shigematsu, A., Rivenson, A., Mu, B., Hoffmann, D., Evaluation of the effects of cotinine and nicotine-N′-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. J. Natl. Cancer Inst. 75 (1985), 1075–1081.
104. Lee, D.C., Rizer, J., Selenica, M.L., Reid, P., Kraft, C., Johnson, A., Blair, L., Gordon, M.N., Dickey, C.A., Morgan, D., LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J. Neuroinflammation, 7, 2010, 56.
105. Lee, J.T., Xu, J., Lee, J.M., Ku, G., Han, X., Yang, D.I., Chen, S., Hsu, C.Y., Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 164 (2004), 123–131.
106. Lee, M., McGeer, E., McGeer, P.L., Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis. Neurobiol. Aging 36 (2015), 42–52.
107. Leiser, S.C., Bowlby, M.R., Comery, T.A., Dunlop, J., A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol. Ther. 122 (2009), 302–311.
108. Li, D.J., Zhao, T., Xin, R.J., Wang, Y.Y., Fei, Y.B., Shen, F.M., Activation of alpha7 nicotinic acetylcholine receptor protects against oxidant stress damage through reducing vascular peroxidase-1 in a JNK signaling-dependent manner in endothelial cells. Cell Physiol. Biochem. 33 (2014), 468–478.
109. Lieberman, J.A., Dunbar, G., Segreti, A.C., Girgis, R.R., Seoane, F., Beaver, J.S., Duan, N., Hosford, D.A., A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. Neuropsychopharmacology 38 (2013), 968–975.
110. Liu, J., Ma, Y., Tian, S., Zhang, L., Zhao, M., Zhang, Y., Xu, D., T cells promote the regeneration of neural precursor cells in the hippocampus of Alzheimer's disease mice. Neural Regen. Res. 9 (2014), 1541–1547.
111. Livingstone, P.D., Dickinson, J.A., Srinivasan, J., Kew, J.N., Wonnacott, S., Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596. J. Mol. Neurosci. 40 (2010), 172–176.
112. Lloyd, A.J., Grace, J.B., Jaros, E., Perry, R.H., Fairbairn, A.F., Swann, A.G., O'Brien, J.T., McKeith, I.G., Depression in late life, cognitive decline and white matter pathology in two clinico-pathologically investigated cases. Int. J. Geriatr. Psychiatry 16 (2001), 281–287.
113. Lok, J., Zhao, S., Leung, W., Seo, J.H., Navaratna, D., Wang, X., Whalen, M.J., Lo, E.H., Neuregulin-1 effects on endothelial and blood–brain-barrier permeability after experimental injury. Transl. Stroke Res. 3:Suppl. 1 (2012), S119–S124.
114. Lopez-Hernandez, G.Y., Thinschmidt, J.S., Morain, P., Trocme-Thibierge, C., Kem, W.R., Soti, F., Papke, R.L., Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795. Neuropharmacology 56 (2009), 821–830.
115. Luber-Narod, J., Rogers, J., Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett. 94 (1988), 17–22.
116. Ludwig, J., Hoffle-Maas, A., Samochocki, M., Luttmann, E., Albuquerque, E.X., Fels, G., Maelicke, A., Localization by site-directed mutagenesis of a galantamine binding site on alpha7 nicotinic acetylcholine receptor extracellular domain. J. Recept Signal Transduct. Res. 30 (2010), 469–483.
117. Luo, J., Ho, P.P., Buckwalter, M.S., Hsu, T., Lee, L.Y., Zhang, H., Kim, D.K., Kim, S.J., Gambhir, S.S., Steinman, L., Wyss-Coray, T., Glia-dependent TGF-beta signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J. Clin. Invest. 117 (2007), 3306–3315.
118. Maelicke, A., Hoeffle-Maas, A., Ludwig, J., Maus, A., Samochocki, M., Jordis, U., Koepke, A.K., Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J. Mol. Neurosci. 40 (2010), 135–137.
119. Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E.X., Zerlin, M., Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol. Psychiatry 49 (2001), 279–288.
120. Majumdar, A., Chung, H., Dolios, G., Wang, R., Asamoah, N., Lobel, P., Maxfield, F.R., Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages. Neurobiol. Aging 29 (2008), 707–715.
121. Maldifassi, M.C., Atienza, G., Arnalich, F., Lopez-Collazo, E., Cedillo, J.L., Martin-Sanchez, C., Bordas, A., Renart, J., Montiel, C., A new IRAK-M-mediated mechanism implicated in the anti-inflammatory effect of nicotine via alpha7 nicotinic receptors in human macrophages. PLoS ONE, 9, 2014, e108397.
122. Mancardi, G.L., Liwnicz, B.H., Mandybur, T.I., Fibrous astrocytes in Alzheimer's disease and senile dementia of Alzheimer's type. Acta Neuropathol. 61 (1983), 76–80.
123. Marosova, L., Neradil, P., Zilka, N., How can viruses influence the neuroinflammation and neurodegeneration in the aged human brain. Acta Virol. 57 (2014), 273–281.
124. Martelli, D., McKinley, M.J., McAllen, R.M., The cholinergic anti-inflammatory pathway: a critical review. Auton Neurosci. 182 (2014), 65–69.
125. McCarty, J.H., Cell adhesion and signaling networks in brain neurovascular units. Curr. Opin. Hematol. 16 (2009), 209–214.
126. McGeer, E.G., McGeer, P.L., Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J. Alzheimers Dis. 19 (2010), 355–361.
127. McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., Immune system response in Alzheimer's disease. Can. J. Neurol. Sci. 16 (1989), 516–527.
128. McGeer, P.L., Itagaki, S., Boyes, B.E., McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988), 1285–1291.
129. McGeer, P.L., McGeer, E.G., The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21 (1995), 195–218.
130. McGeer, P.L., McGeer, E.G., Autotoxicity and Alzheimer disease. Arch. Neurol. 57 (2000), 789–790.
131. McGeer, P.L., McGeer, E.G., Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22 (2001), 799–809.
132. McGeer, P.L., McGeer, E.G., Innate immunity, local inflammation, and degenerative disease. Sci. Aging Knowledge Environ., 2002, 2002, re3.
133. McGeer, P.L., McGeer, E.G., History of innate immunity in neurodegenerative disorders. Front. Pharmacol., 2, 2011, 77.
134. McGeer, P.L., McGeer, E.G., Targeting microglia for the treatment of Alzheimer's disease. Expert Opin. Ther. Targets, 2013, 1–10.
135. McGeer, P.L., Rogers, J., McGeer, E.G., Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J. Alzheimers Dis. 9 (2006), 271–276.
136. McGeer, P.L., Schulzer, M., McGeer, E.G., Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47 (1996), 425–432.
137. Michaluk, P., Kaczmarek, L., Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Differ. 14 (2007), 1255–1258.
138. Michaluk, P., Kolodziej, L., Mioduszewska, B., Wilczynski, G.M., Dzwonek, J., Jaworski, J., Gorecki, D.C., Ottersen, O.P., Kaczmarek, L., Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J. Biol. Chem. 282 (2007), 16036–16041.
139. Miguel-Alvarez, M., Santos-Lozano, A., Sanchis-Gomar, F., Fiuza-Luces, C., Pareja-Galeano, H., Garatachea, N., Lucia, A., Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 32 (2015), 139–147.
140. Miklossy, J., Doudet, D.D., Schwab, C., Yu, S., McGeer, E.G., McGeer, P.L., Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 197 (2006), 275–283.
141. Mitew, S., Kirkcaldie, M.T., Halliday, G.M., Shepherd, C.E., Vickers, J.C., Dickson, T.C., Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol. 119 (2010), 567–577.
142. Miyauchi, K., Urano, E., Takeda, S., Murakami, T., Okada, Y., Cheng, K., Yin, H., Kubo, M., Komano, J., Toll-like receptor (TLR) 3 as a surrogate sensor of retroviral infection in human cells. Biochem. Biophys. Res. Commun. 424 (2012), 519–523.
143. Monod, J., Wyman, J., Changeux, J.P., On the nature of allosteric transitions: a plausible model. J. Mol. Biol. 12 (1965), 88–118.
144. Mushtaq, G., Khan, J.A., Kumosani, T.A., Kamal, M.A., Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms. Saudi J. Biol. Sci. 22 (2015), 4–13.
145. Nacmias, B., Piaceri, I., Bagnoli, S., Tedde, A., Piacentini, S., Sorbi, S., Genetics of Alzheimer's disease and frontotemporal dementia. Curr. Mol. Med., 2014 [Epub ahead of print].
146. Nagai, T., McGeer, P.L., Peng, J.H., McGeer, E.G., Dolman, C.E., Choline acetyltransferase immunohistochemistry in brains of Alzheimer's disease patients and controls. Neurosci. Lett. 36 (1983), 195–199.
147. Nagele, R.G., D'Andrea, M.R., Lee, H., Venkataraman, V., Wang, H.Y., Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971 (2003), 197–209.
148. Najem, D., Bamji-Mirza, M., Chang, N., Liu, Q.Y., Zhang, W., Insulin resistance, neuroinflammation, and Alzheimer's disease. Rev. Neurosci. 25 (2014), 509–525.
149. Nicoll, J.A., Barton, E., Boche, D., Neal, J.W., Ferrer, I., Thompson, P., Vlachouli, C., Wilkinson, D., Bayer, A., Games, D., Seubert, P., Schenk, D., Holmes, C., Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 65 (2006), 1040–1048.
150. Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O., Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003), 448–452.
151. Nimmerjahn, A., Astrocytes going live: advances and challenges. J. Physiol. 587 (2009), 1639–1647.
152. Nimmerjahn, A., Kirchhoff, F., Helmchen, F., Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308 (2005), 1314–1318.
153. Nordberg, A., Hellstrom-Lindahl, E., Lee, M., Johnson, M., Mousavi, M., Hall, R., Perry, E., Bednar, I., Court, J., Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J. Neurochem. 81 (2002), 655–658.
154. Norris, C.M., Blalock, E.M., Chen, K.C., Porter, N.M., Landfield, P.W., Calcineurin enhances L-type Ca(2+) channel activity in hippocampal neurons: increased effect with age in culture. Neuroscience 110 (2002), 213–225.
155. Norris, C.M., Kadish, I., Blalock, E.M., Chen, K.C., Thibault, V., Porter, N.M., Landfield, P.W., Kraner, S.D., Calcineurin triggers reactive/inflammatory processes in astrocytes and is upregulated in aging and Alzheimer's models. J. Neurosci. 25 (2005), 4649–4658.
156. Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26 (2006), 10129–10140.
157. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P., Akbari, Y., LaFerla, F.M., Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003), 409–421.
158. Ono, K., Hasegawa, K., Yamada, M., Naiki, H., Nicotine breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. Biol. Psychiatry 52 (2002), 880–886.
159. Ono, K., Naiki, H., Yamada, M., The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr. Pharm. Des. 12 (2006), 4357–4375.
160. Orgogozo, J.M., Gilman, S., Dartigues, J.F., Laurent, B., Puel, M., Kirby, L.C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., Michel, B.F., Boada, M., Frank, A., Hock, C., Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003), 46–54.
161. Ostrowitzki, S., Deptula, D., Thurfjell, L., Barkhof, F., Bohrmann, B., Brooks, D.J., Klunk, W.E., Ashford, E., Yoo, K., Xu, Z.X., Loetscher, H., Santarelli, L., Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69 (2012), 198–207.
162. Overmyer, M., Helisalmi, S., Soininen, H., Laakso, M., Riekkinen, P. Sr., Alafuzoff, I., Astrogliosis and the ApoE genotype. an immunohistochemical study of postmortem human brain tissue. Dement. Geriatr. Cogn. Disord. 10 (1999), 252–257.
163. Palma, E., Maggi, L., Miledi, R., Eusebi, F., Effects of Zn2+ on wild and mutant neuronal alpha7 nicotinic receptors. Proc. Natl. Acad. Sci. U.S.A. 95 (1998), 10246–10250.
164. Panza, F., Solfrizzi, V., Imbimbo, B.P., Tortelli, R., Santamato, A., Logroscino, G., Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert. Rev. Clin. Immunol. 10 (2014), 405–419.
165. Parachikova, A., Agadjanyan, M.G., Cribbs, D.H., Blurton-Jones, M., Perreau, V., Rogers, J., Beach, T.G., Cotman, C.W., Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 28 (2007), 1821–1833.
166. Paresce, D.M., Chung, H., Maxfield, F.R., Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J. Biol. Chem. 272 (1997), 29390–29397.
167. Paris, D., Beaulieu-Abdelahad, D., Abdullah, L., Bachmeier, C., Ait-Ghezala, G., Reed, J., Verma, M., Crawford, F., Mullan, M., Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. Eur. J. Pharmacol. 698 (2013), 145–153.
168. Patel, S., Grizzell, J.A., Holmes, R., Zeitlin, R., Solomon, R., Sutton, T.L., Rohani, A., Charry, L.C., Iarkov, A., Mori, T., Echeverria Moran, V., Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice. Front. Aging Neurosci., 6, 2014, 162.
169. Paulson, J.B., Ramsden, M., Forster, C., Sherman, M.A., McGowan, E., Ashe, K.H., Amyloid plaque and neurofibrillary tangle pathology in a regulatable mouse model of Alzheimer's disease. Am. J. Pathol. 173 (2008), 762–772.
170. Pavlov, V.A., Ochani, M., Yang, L.H., Gallowitsch-Puerta, M., Ochani, K., Lin, X., Levi, J., Parrish, W.R., Rosas-Ballina, M., Czura, C.J., Larosa, G.J., Miller, E.J., Tracey, K.J., Al-Abed, Y., Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med. 35 (2007), 1139–1144.
171. Pavlov, V.A., Wang, H., Czura, C.J., Friedman, S.G., Tracey, K.J., The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol. Med. 9 (2003), 125–134.
172. Perrin, R.J., Fagan, A.M., Holtzman, D.M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461 (2009), 916–922.
173. Perry, G., Nunomura, A., Hirai, K., Takeda, A., Aliev, G., Smith, M.A., Oxidative damage in Alzheimer's disease: the metabolic dimension. Int. J. Dev. Neurosci. 18 (2000), 417–421.
174. Pooler, A.M., Polydoro, M., Wegmann, S.K., Pitstick, R., Kay, K.R., Sanchez, L., Carlson, G.A., Gomez-Isla, T., Albers, M.W., Spires-Jones, T.L., Hyman, B.T., Tau-amyloid interactions in the rTgTauEC model of early Alzheimer's disease suggest amyloid-induced disruption of axonal projections and exacerbated axonal pathology. J. Comp. Neurol. 521 (2013), 4236–4248.
175. Posadas, I., Lopez-Hernandez, B., Cena, V., Nicotinic receptors in neurodegeneration. Curr. Neuropharmacol. 11 (2013), 298–314.
176. Raivich, G., Like cops on the beat: the active role of resting microglia. Trends Neurosci. 28 (2005), 571–573.
177. Rehani, K., Scott, D.A., Renaud, D., Hamza, H., Williams, L.R., Wang, H., Martin, M., Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim. Biophys. Acta 1783 (2008), 375–382.
178. Rodriguez, J.J., Olabarria, M., Chvatal, A., Verkhratsky, A., Astroglia in dementia and Alzheimer's disease. Cell Death Differ. 16 (2009), 378–385.
179. Rogers, J., Luber-Narod, J., Styren, S.D., Civin, W.H., Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol. Aging 9 (1988), 339–349.
180. Rosas-Ballina, M., Goldstein, R.S., Gallowitsch-Puerta, M., Yang, L., Valdes-Ferrer, S.I., Patel, N.B., Chavan, S., Al-Abed, Y., Yang, H., Tracey, K.J., The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol. Med. 15 (2009), 195–202.
181. Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., Abramsky, O., Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63 (2006), 1459–1467.
182. Rossor, M.N., Focal changes in Alzheimer's disease and cholinergic hypothesis. Lancet, 2, 1983, 465.
183. Rostasy, K.M., Inflammation and neuroaxonal injury in multiple sclerosis and AIDS dementia complex: implications for neuroprotective treatment. Neuropediatrics 36 (2005), 230–239.
184. Roth, A.D., Ramirez, G., Alarcon, R., Von Bernhardi, R., Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. Biol. Res. 38 (2005), 381–387.
185. Saez, E.T., Pehar, M., Vargas, M.R., Barbeito, L., Maccioni, R.B., Production of nerve growth factor by beta-amyloid-stimulated astrocytes induces p75NTR-dependent tau hyperphosphorylation in cultured hippocampal neurons. J. Neurosci. Res. 84 (2006), 1098–1106.
186. Saez, T.E., Pehar, M., Vargas, M., Barbeito, L., Maccioni, R.B., Astrocytic nitric oxide triggers tau hyperphosphorylation in hippocampal neurons. In Vivo 18 (2004), 275–280.
187. Saiga, H., Shimada, Y., Takeda, K., Innate immune effectors in mycobacterial infection. Clin. Dev. Immunol., 2011, 2012, 347594.
188. Salloway, S., Sperling, R., Brashear, H.R., Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N. Engl. J. Med., 370, 2014, 1460.
189. Salomon, A.R., Marcinowski, K.J., Friedland, R.P., Zagorski, M.G., Nicotine inhibits amyloid formation by the beta-peptide. Biochemistry 35 (1996), 13568–13578.
190. Samochocki, M., Hoffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E.F., Lubbert, H., Albuquerque, E.X., Maelicke, A., Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305 (2003), 1024–1036.
191. Samochocki, M., Zerlin, M., Jostock, R., Groot Kormelink, P.J., Luyten, W.H., Albuquerque, E.X., Maelicke, A., Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 176 (2000), 68–73.
192. Saul, A., Sprenger, F., Bayer, T.A., Wirths, O., Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34 (2013), 2564–2573.
193. Seo, J.H., Guo, S., Lok, J., Navaratna, D., Whalen, M.J., Kim, K.W., Lo, E.H., Neurovascular matrix metalloproteinases and the blood–brain barrier. Curr. Pharm. Des. 18 (2012), 3645–3648.
194. Sha, S., Xing, X.N., Cao, Y.P., Active immunotherapy facilitates Abeta plaque removal following through microglial activation without obvious T cells infiltrating the CNS. J. Neuroimmunol. 274 (2014), 62–70.
195. Shaftel, S.S., Carlson, T.J., Olschowka, J.A., Kyrkanides, S., Matousek, S.B., O'Banion, M.K., Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 27 (2007), 9301–9309.
196. Shao, C.Y., Mirra, S.S., Sait, H.B., Sacktor, T.C., Sigurdsson, E.M., Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Abeta and tau pathology in transgenic mouse models of Alzheimer's disease. Acta Neuropathol. 122 (2011), 285–292.
197. Shi, J., Wang, Q., Johansson, J.U., Liang, X., Woodling, N.S., Priyam, P., Loui, T.M., Merchant, M., Breyer, R.M., Montine, T.J., Andreasson, K., Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease. Ann. Neurol. 72 (2012), 788–798.
198. Simard, A.R., Rivest, S., Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol. Psychiatry 11 (2006), 327–335.
199. Simard, M., Arcuino, G., Takano, T., Liu, Q.S., Nedergaard, M., Signaling at the gliovascular interface. J. Neurosci. 23 (2003), 9254–9262.
200. Simpson, J.E., Ince, P.G., Lace, G., Forster, G., Shaw, P.J., Matthews, F., Savva, G., Brayne, C., Wharton, S.B., Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol. Aging 31 (2010), 578–590.
201. Sofroniew, M.V., Vinters, H.V., Astrocytes: biology and pathology. Acta Neuropathol. 119 (2010), 7–35.
202. Srivareerat, M., Tran, T.T., Salim, S., Aleisa, A.M., Alkadhi, K.A., Chronic nicotine restores normal Abeta levels and prevents short-term memory and E-LTP impairment in Abeta rat model of Alzheimer's disease. Neurobiol. Aging 32 (2011), 834–844.
203. Streit, W.J., Xue, Q.S., Human CNS immune senescence and neurodegeneration. Curr. Opin. Immunol. 29 (2014), 93–96.
204. Streit, W.J., Xue, Q.S., Tischer, J., Bechmann, I., Microglial pathology. Acta Neuropathol. Commun., 2, 2014, 142.
205. Struble, R.G., Cork, L.C., Whitehouse, P.J., Price, D.L., Cholinergic innervation in neuritic plaques. Science 216 (1982), 413–415.
206. Suzuki, T., Hide, I., Matsubara, A., Hama, C., Harada, K., Miyano, K., Andra, M., Matsubayashi, H., Sakai, N., Kohsaka, S., Inoue, K., Nakata, Y., Microglial alpha7 nicotinic acetylcholine receptors drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective role. J. Neurosci. Res. 83 (2006), 1461–1470.
207. Takata, K., Kitamura, Y., Saeki, M., Terada, M., Kagitani, S., Kitamura, R., Fujikawa, Y., Maelicke, A., Tomimoto, H., Taniguchi, T., Shimohama, S., Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J. Biol. Chem. 285 (2010), 40180–40191.
208. Takeda, K., Akira, S., Roles of Toll-like receptors in innate immune responses. Genes Cells 6 (2001), 733–742.
209. Takeda, K., Akira, S., Microbial recognition by Toll-like receptors. J. Dermatol. Sci. 34 (2004), 73–82.
210. Takeda, K., Akira, S., TLR signaling pathways. Semin Immunol. 16 (2004), 3–9.
211. Takeda, K., Kaisho, T., Akira, S., Toll-like receptors. Annu. Rev. Immunol. 21 (2003), 335–376.
212. Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., Akira, S., Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11 (1999), 443–451.
213. Takeuchi, O., Kawai, T., Sanjo, H., Copeland, N.G., Gilbert, D.J., Jenkins, N.A., Takeda, K., Akira, S., TLR6: A novel member of an expanding toll-like receptor family. Gene 231 (1999), 59–65.
214. Terry, A.V. Jr., Callahan, P.M., Bertrand, D., R-(+) and s-(−) isomers of cotinine augment cholinergic responses in vitro and in vivo. J. Pharmacol. Exp. Ther. 352 (2015), 405–418.
215. Thomsen, M.S., Mikkelsen, J.D., The alpha7 nicotinic acetylcholine receptor ligands methyllycaconitine, NS6740 and GTS-21 reduce lipopolysaccharide-induced TNF-alpha release from microglia. J. Neuroimmunol. 251 (2012), 65–72.
216. Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F.J., Grosjean, M.E., Zommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., Buee, L., Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 9 (2012), 397–405.
217. Uteshev, V.V., Meyer, E.M., Papke, R.L., Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. Brain Res. 948 (2002), 33–46.
218. Uteshev, V.V., Meyer, E.M., Papke, R.L., Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors. J Neurophysiol 89 (2003), 1797–1806.
219. Velez-Fort, M., Audinat, E., Angulo, M.C., Functional alpha 7-containing nicotinic receptors of NG2-expressing cells in the hippocampus. Glia 57 (2009), 1104–1114.
220. Villoslada, P., Moreno, B., Melero, I., Pablos, J.L., Martino, G., Uccelli, A., Montalban, X., Avila, J., Rivest, S., Acarin, L., Appel, S., Khoury, S.J., McGeer, P., Ferrer, I., Delgado, M., Obeso, J., Schwartz, M., Immunotherapy for neurological diseases. Clin. Immunol. 128 (2008), 294–305.
221. Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Yang, H., Ulloa, L., Al-Abed, Y., Czura, C.J., Tracey, K.J., Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421 (2003), 384–388.
222. Wang, P.N., Chou, K.H., Lirng, J.F., Lin, K.N., Chen, W.T., Lin, C.P., Multiple diffusivities define white matter degeneration in amnestic mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 30 (2012), 423–437.
223. White, J.A., Manelli, A.M., Holmberg, K.H., Van Eldik, L.J., Ladu, M.J., Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18 (2005), 459–465.
224. Whitehouse, P.J., Martino, A.M., Antuono, P.G., Lowenstein, P.R., Coyle, J.T., Price, D.L., Kellar, K.J., Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371 (1986), 146–151.
225. Whitehouse, P.J., Martino, A.M., Wagster, M.V., Price, D.L., Mayeux, R., Atack, J.R., Kellar, K.J., Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 38 (1988), 720–723.
226. Whitman, G.T., Cotman, C.W., Oligodendrocyte degeneration in AD. Neurobiol. Aging 25 (2004), 33–36.
227. Williams, D.K., Peng, C., Kimbrell, M.R., Papke, R.L., Intrinsically low open probability of alpha7 nicotinic acetylcholine receptors can be overcome by positive allosteric modulation and serum factors leading to the generation of excitotoxic currents at physiological temperatures. Mol. Pharmacol. 82 (2012), 746–759.
228. Williams, D.K., Wang, J., Papke, R.L., Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. Biochem. Pharmacol. 82 (2011), 915–930.
229. Winterer, G., Gallinat, J., Brinkmeyer, J., Musso, F., Kornhuber, J., Thuerauf, N., Rujescu, D., Favis, R., Sun, Y., Franc, M.A., Ouwerkerk-Mahadevan, S., Janssens, L., Timmers, M., Streffer, J.R., Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology 64 (2013), 197–204.
230. Wyss-Coray, T., Killing pain, killing neurons?. Nat. Med. 11 (2005), 472–473.
231. Wyss-Coray, T., Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 12 (2006), 1005–1015.
232. Wyss-Coray, T., Lin, C., Yan, F., Yu, G.Q., Rohde, M., McConlogue, L., Masliah, E., Mucke, L., TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7 (2001), 612–618.
233. Wyss-Coray, T., Loike, J.D., Brionne, T.C., Lu, E., Anankov, R., Yan, F., Silverstein, S.C., Husemann, J., Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 9 (2003), 453–457.
234. Wyss-Coray, T., McConlogue, L., Kindy, M., Schmidt, A.M., Du Yan, S., Stern, D.M., Key signaling pathways regulate the biological activities and accumulation of amyloid-beta. Neurobiol. Aging 22 (2001), 967–973.
235. Wyss-Coray, T., Mucke, L., Ibuprofen, inflammation and Alzheimer disease. Nat. Med. 6 (2000), 973–974.
236. Wyss-Coray, T., Mucke, L., Inflammation in neurodegenerative disease—a double-edged sword. Neuron 35 (2002), 419–432.
237. Wyss-Coray, T., Rogers, J., Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med., 2, 2012, a006346.
238. Wyss-Coray, T., Yan, F., Lin, A.H., Lambris, J.D., Alexander, J.J., Quigg, R.J., Masliah, E., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 10837–10842.
239. Xia, D., Li, C., Gotz, J., Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines. Biochim. Biophys. Acta 1852 (2015), 913–924.
240. Xu, D.E., Zhang, W.M., Yang, Z.Z., Zhu, H.M., Yan, K., Li, S., Bagnard, D., Dawe, G.S., Ma, Q.H., Xiao, Z.C., Amyloid precursor protein at node of Ranvier modulates nodal formation. Cell Adhesion Migr. 8 (2014), 396–403.
241. Xu, J., Chen, S., Ahmed, S.H., Chen, H., Ku, G., Goldberg, M.P., Hsu, C.Y., Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci., 21, 2001, RC118.
242. Yong, V.W., Promoting remyelination by reducing an inhibitory microenvironment. Rinsho Shinkeigaku, 50, 2010, 869.
243. Yong, V.W., Marks, S., The interplay between the immune and central nervous systems in neuronal injury. Neurology 74 Suppl 1 (2010), S9–S16.
244. Young, J.W., Geyer, M.A., Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochem. Pharmacol. 86 (2013), 1122–1132.
245. Zamani, M.R., Allen, Y.S., Nicotine and its interaction with beta-amyloid protein: a short review. Biol. Psychiatry 49 (2001), 221–232.
246. Zandi, P.P., Anthony, J.C., Hayden, K.M., Mehta, K., Mayer, L., Breitner, J.C., Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59 (2002), 880–886.